←Palliative Care
Study register · detail Prospektive Fallserie · Palliative Care · 1995

An efficient new cannabinoid antiemetic in pediatric oncology.

Abrahamov et al. ·Life Sciences
Clear benefit GRADE Very low 183 citations
Samplen = 8 Pat.
Durationup to 8 months
EndpointVomiting frequency
Blindingn.a.
DesignProspektive Fallserie
Cannabinoidthc
Routeoral
Key finding

Delta-8-THC completely prevented chemotherapy-induced vomiting in all treated children.

Summary

n=8 pediatric oncology patients (3–13 years) undergoing antineoplastic therapy, Delta-8-THC as antiemetic supportive measure (480 treatments, up to 8 months); complete prevention of chemotherapy-induced emesis in 100% of administrations; side effects negligible — relevant for palliative symptom control in children with hematological malignancies.

P
PopulationChildren with hematological cancers undergoing chemotherapy, n=8, age 3–13 years
I
InterventionDelta-8-THC 18 mg/m² in edible oil, oral, 2 h before chemotherapy, then every 6 h for 24 h
O
OutcomeVomiting completely prevented in all 480 treatment cycles; side effects negligible
Confidence in the evidence
Very low

The lowest GRADE level, the effect estimate remains uncertain.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Abrahamov A, Abrahamov A, Mechoulam R.
DOI 10.1016/0024-3205(95)00194-b↗
Design: Prospektive Fallserie
Share
Abstract
Delta-8-tetrahydrocannabinol (delta-8-THC), a cannabinoid with lower psychotropic potency than the main Cannabis constituent, delta-9-tetrahydrocannabinol (delta-9-THC), was administered (18 mg/m2 in edible oil, p.o.) to eight children, aged 3-13 years with various hematologic cancers, treated with different antineoplastic drugs for up to 8 months. The total number of treatments with delta-8-THC so far is 480. The THC treatment started two hours before each antineoplastic treatment and was continued every 6 hrs for 24 hours. Vomiting was completely prevented. The side effects observed were negligible.
Indication
Further studies on Palliative Care
All studies →
S Hauser et al. · 2023 · The Cochrane database of systematic reviews
53 citations
Cannabis-based medicines and medical cannabis for adults with cancer pain.
No benefit demonstrated Meta-Analyse

Cochrane SR zu Cannabis-basierten Medikamenten bei Tumorschmerz (Erwachsene). Evaluiert Nutzen und Schäden vs. Placebo oder etablierte Analgetika; primäre Outcomes: ≤mild pain, PGIC much/very much improved, Withdrawals due to AE. Suche bis 26.01.2023, Einschlusskriterien: doppelblinde RCTs, ≥10 Teilnehmende pro Arm.

10.1002/14651858.cd014915.pub2 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; moderate Evidenz für chronischen Schmerz (inkl. Krebs-assoziierter Schmerz) und MS-Spastik, schwache Evidenz für Chemotherapie-induzierte Übelkeit/Erbrechen, Appetitanregung bei HIV/AIDS und palliative Symptomkontrolle.

10.1001/jama.2015.6358 View study →
A Doppen et al. · 2022 · Journal of pain and symptom management
44 citations
Cannabis in Palliative Care: A Systematic Review of Current Evidence.
Mixed Systematic Review

Systematische Review zu Cannabis in der Palliativmedizin; k=52 Studien (20 RCTs, 32 nicht-randomisierte), n=4.786 Teilnehmende (Krebs n=4.491, Demenz n=43, AIDS n=235, Spastik n=16). Positive Behandlungseffekte (p<0.05) für einige Cannabis-Produkte bei Schmerz, Übelkeit/Erbrechen, Appetit, Schlaf, Fatigue bei Krebs-Patienten; Appetit/Agitation bei Demenz; Appetit/Übelkeit bei AIDS. Evidenzqualität durchgehend 'very low' oder 'low'. Meta-Analyse nicht durchführbar aufgrund Heterogenität der Produkte und Outcomes.

10.1016/j.jpainsymman.2022.06.002 View study →

The impediment to action advances action. — Marcus Aurelius